Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART

UnknownOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
HIV-1-infection
Interventions
DRUG

Elpida® + 2 NRTIs

Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy

Trial Locations (11)

105275

RECRUITING

"The State Budgetary Healthcare Institution of Moscow Infectious Clinical Hospital No. 2 of the Moscow City Health Department (SGBU ICD No. 2 DZM), Moscow City Center for AIDS Prevention and Control of the Moscow City Health Department", Moscow

190020

RECRUITING

"State Public Health Institution of the Leningrad Region Center for the Prevention and Control of AIDS and Infectious Diseases", Saint Petersburg

190103

RECRUITING

"St. Petersburg State Budgetary Healthcare Institution Center for the Prevention and Control of AIDS and Infectious Diseases", Saint Petersburg

344116

RECRUITING

Center for AIDS Prevention and Control, Rostov-on-Don

350015

RECRUITING

Clinical Center for AIDS Prevention and Control, Krasnodar

414041

RECRUITING

Regional AIDS Prevention and Control Center, Astrakhan

454038

RECRUITING

Regional Center for the Prevention and Control of AIDS and Infectious Diseases, Chelyabinsk

630099

RECRUITING

"State Regional Clinical Hospital City Infectious Clinical Hospital No. 1", Novosibirsk

649002

RECRUITING

Center for AIDS Prevention and Control, Gorno-Altaysk

656010

RECRUITING

Altai Regional Center for the Prevention and Control of AIDS and Infectious Diseases, Barnaul

680031

RECRUITING

Center for the Prevention and Control of AIDS and Infectious Diseases, Khabarovsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Viriom

INDUSTRY